Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data

por Engmann, Natalie J, Sheinson, Danny, Bawa, Komal, Ng, Carmen D, Pardo, Gabriel
Publicado 2021

Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab

por Geiger, Caroline K., Sheinson, Danny, To, Tu My, Jones, David, Bonine, Nicole G.
Publicado 2023